A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Results (n=20) assessing efficacy and safety of apatinib plus chemotherapy in patients with advanced small cell lung cancer, presented at the 20th World Conference on Lung Cancer.
- 19 Aug 2019 Status changed from not yet recruiting to recruiting.
- 08 Jun 2018 New trial record